Cargando…
Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics
To date, the most studied drug in anti-aging research is the mTOR inhibitor – rapamycin. Despite its almost perfect anti-aging profile, rapamycin exerts one significant limitation – inappropriate physicochemical properties. Therefore, we have decided to utilize virtual high-throughput screening and...
Autores principales: | Chrienova, Zofia, Rysanek, David, Oleksak, Patrik, Stary, Dorota, Bajda, Marek, Reinis, Milan, Mikyskova, Romana, Novotny, Ondrej, Andrys, Rudolf, Skarka, Adam, Vasicova, Pavla, Novak, Josef, Valis, Martin, Kuca, Kamil, Hodny, Zdenek, Nepovimova, Eugenie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767416/ https://www.ncbi.nlm.nih.gov/pubmed/36561137 http://dx.doi.org/10.3389/fnagi.2022.1048260 |
Ejemplares similares
-
Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021) -
Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities
por: Chrienova, Zofia, et al.
Publicado: (2022) -
The role of mTOR in age-related diseases
por: Chrienova, Zofia, et al.
Publicado: (2021) -
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells
por: Mikyskova, Romana, et al.
Publicado: (2023) -
Neuropharmacology of Cevimeline and Muscarinic Drugs—Focus on Cognition and Neurodegeneration
por: Oleksak, Patrik, et al.
Publicado: (2021)